Top 15 Companies in Global Cancer Microbiome Sequencing Market: Global Share, Market Size, Revenue Report (2026–2035)

Description

 

According to a research report published by Spherical Insights & Consulting, the Global Cancer Microbiome Sequencing Market Size is projected to grow from USD 395.2 Million in 2025 to USD 2471.2 Million by 2035, at a CAGR of 20.12% during the forecast period 2026–2035. The market shows rapid expansion due to rising cancer rates, increasing use of next-generation sequencing (NGS), and growing funding for microbiome diagnostics and precision medicine research.

 

Introduction

 

The cancer microbiome sequencing market refers to the global industry that studies microbial communities in tumor environments through advanced genomic sequencing techniques. These microbiomes affect cancer progression, immune system functioning, and treatment results. Research on microbiomes in oncology is advancing through government and institutional programs, which include National Institutes of Health (NIH) funding and cancer research initiatives. The combination of microbiome sequencing and precision medicine systems enables medical professionals to create customized cancer treatments and better diagnostic methods.

In July 2025, the National Institutes of Health announced that the Human Microbiome Project produced 3000 microbial genomes, which were obtained from 300 study subjects. The project now helps researchers worldwide who study sequence-based cancer microbiome research and biomarker identification for their oncology studies. The market presents substantial growth potential because oncology research and clinical diagnostics need early cancer detection, biomarker identification, drug development, and customized treatment methods.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

 

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Cancer Microbiome Sequencing Market.

 

Cancer Microbiome Sequencing Market Size & Statistics

 

• The Market Size for Cancer Microbiome Sequencing Was Estimated to be worth USD 395.2 Million in 2025.

• The Market is Going to Expand at a CAGR of 20.12% between 2026 and 2035.

• The Global Cancer Microbiome Sequencing Market Size is anticipated to reach USD 2471.2 Million by 2035.

• North America is expected to generate the largest demand during the forecast period in the Cancer Microbiome Sequencing Market.

• Asia Pacific is expected to grow the fastest during the forecast period in the Cancer Microbiome Sequencing Market.

 

Market Segmentation:

 

Global Cancer Microbiome Sequencing Market Size, Share, By Technology (Next-Generation Sequencing and Polymerase Chain Reaction), By End-User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, and Hospitals and Diagnostic Laboratories), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2026 - 2035

 

Regional growth and demand

 

Asia Pacific is expected to grow the fastest during the forecast period in the cancer microbiome sequencing market. Asia Pacific is expected to grow the fastest during the forecast period due to increasing healthcare investments, rising cancer cases, and expanding biotechnology sectors in countries such as China, India, and Japan. Government-backed cancer research programs are further accelerating market growth in the region. In March 2026, ASTAR Genome Institute of Singapore advanced cancer microbiome sequencing standards, improving metagenomic accuracy and enabling reliable biomarker discovery, strengthening APAC precision oncology research capabilities. In March 2026, the National University of Singapore launched a cancer microbiome sequencing guidelines initiative, enhancing clinical reproducibility and accelerating adoption of sequencing-based microbiome diagnostics across Asia-Pacific oncology research networks.

 

North America is expected to generate the largest demand during the forecast period in the cancer microbiome sequencing market. North America is expected to dominate the cancer microbiome sequencing market due to strong healthcare infrastructure, high cancer incidence, and significant R&D investments. In April 2025, Metabolon Inc launched an integrated microbiome sequencing and metabolomics solution, combining metagenomics and bioinformatics to enhance cancer microbiome research, biomarker discovery, and precision oncology applications across North America. In August 2025, the cancer microbiome sequencing market grew rapidly with 21% CAGR, driven by next-generation sequencing advancements and increasing oncology applications, accelerating product launches and research innovations across North America.

 

 

Top 10 Trends in the Cancer Microbiome Sequencing Market

1. Growth in next-generation sequencing (NGS) adoption
2. Rising demand for personalized cancer treatment
3. Expansion of microbiome-based diagnostics
4. Increasing investment in cancer research
5. Integration of AI in microbiome analysis
6. Growth in biomarker discovery
7. Increasing use in immunotherapy research
8. Development of cost-effective sequencing platforms
9. Expansion of clinical applications
10. Strategic collaborations between biotech firms

 

1. Growth in next-generation sequencing (NGS) adoption

Next-generation sequencing technologies are rapidly transforming cancer microbiome analysis by enabling high-throughput and accurate microbial profiling. 

 

2. Rising demand for personalized cancer treatment

Microbiome sequencing plays a crucial role in personalized medicine by identifying microbial signatures that influence cancer progression and treatment response.

 

3. Expansion of microbiome-based diagnostics

The development of microbiome-based diagnostic tools is gaining momentum as researchers discover links between microbial composition and cancer types.

 

3. Increasing investment in cancer research

Governments, pharmaceutical companies, and research institutions are significantly increasing investments in cancer microbiome studies.

 

4. Integration of AI in microbiome analysis

Artificial intelligence and bioinformatics tools are being integrated with microbiome sequencing to analyze large datasets efficiently.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Cancer Microbiome Sequencing Market.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the cancer microbiome sequencing market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Top 15 Companies Leading the Cancer Microbiome Sequencing Market

1. Illumina Inc.
2. Thermo Fisher Scientific Inc.
3. QIAGEN N.V.
4. PerkinElmer Inc.
5. Novogene Corporation
6. Zymo Research
7. Psomagen Inc.
8. Viome Life Sciences
9. Microbiome Insights Inc.
10. Bio-Rad Laboratories
11. Oxford Nanopore Technologies
12. Agilent Technologies
13. Metabiomics Corp.
14. Invivo Diagnostics
15. Takara Bio Inc.

 

1. Illumina Inc.

Headquarters: San Diego, USA

Illumina Inc. is a leading genomics company founded in 1998 by David Walt, Larry Bock, John Stuelpnagel, and Anthony Czarnik. The company employs approximately 10,000+ people worldwide and operates in over 160 countries. Its estimated 2025 revenue is around USD 4.5-5 billion. Illumina specializes in next-generation sequencing platforms widely used in cancer microbiome research. Key projects include advanced sequencing systems such as NovaSeq and MiSeq platforms for oncology applications. Major markets include North America, Europe, and Asia-Pacific, where genomic research and precision medicine adoption are highest, making Illumina a dominant player in microbiome sequencing technologies.

 

2. Thermo Fisher Scientific Inc.

Headquarters: Waltham, Massachusetts, USA

Thermo Fisher Scientific Inc. was founded in 2006 (merger of Thermo Electron and Fisher Scientific). The company employs over 125,000 people globally and operates in more than 180 countries. Its estimated 2025 revenue exceeds USD 42 billion. The company provides sequencing instruments, reagents, and bioinformatics tools for cancer microbiome analysis. Key projects include Ion Torrent sequencing systems and oncology-focused research solutions. Major markets include North America, Europe, and Asia-Pacific, where strong demand for advanced diagnostics and research tools drives growth. Thermo Fisher is a key contributor to precision oncology and microbiome-based research.

 

3. QIAGEN N.V.

Headquarters: Venlo, Netherlands

QIAGEN N.V. is a global biotechnology company founded in 1984 by Peer M. Schatz and Detlev Riesner. The company employs approximately 6,000+ people worldwide and operates in over 35 countries. Its estimated 2025 revenue is around USD 2.2 billion. QIAGEN focuses on sample preparation technologies, sequencing kits, and bioinformatics solutions used in microbiome research. Key projects include diagnostic kits and genomic analysis platforms supporting cancer research. Major markets include Europe, North America, and Asia-Pacific, where molecular diagnostics adoption is growing rapidly. The company plays a critical role in enabling accurate microbiome sequencing workflows.

 

4. PerkinElmer Inc.

Headquarters: Waltham, Massachusetts, USA

PerkinElmer Inc. is a global life sciences and diagnostics company founded in 1937 by Richard Scott Perkin and Charles Elmer. The company employs approximately 14,000+ people worldwide and operates in over 150 countries. Its estimated 2025 revenue is around USD 3.3 billion. PerkinElmer provides genomic sequencing tools, diagnostic solutions, and research services for cancer microbiome studies. Key projects include oncology research platforms and biomarker discovery tools. Major markets include North America, Europe, and Asia-Pacific, where demand for advanced diagnostic technologies is increasing significantly.

 

5. Novogene Corporation

Headquarters: Beijing, China

Novogene Corporation is a leading genomics services provider founded in 2011 as a subsidiary of BGI Group. The company employs approximately 2,000+ people globally and operates in over 60 countries. Its estimated 2025 revenue is around USD 500-700 million. Novogene specializes in sequencing services, including microbiome and cancer genomics research. Key projects include large-scale genomic sequencing for oncology studies and clinical research collaborations. Major markets include Asia-Pacific, North America, and Europe, where demand for cost-effective sequencing services is growing rapidly. The company is a key player in expanding microbiome sequencing accessibility.

 

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Cancer Microbiome Sequencing Market.

 

Are you ready to discover more about the cancer microbiome sequencing market?

The report provides an in-depth analysis of the leading companies operating in the global cancer microbiome sequencing market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Illumina Inc.

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

1. Thermo Fisher Scientific Inc.
2. QIAGEN N.V.
3. PerkinElmer Inc.
4. Novogene Corporation
5. Zymo Research
6. Psomagen Inc.
7. Viome Life Sciences
8. Microbiome Insights Inc.
9. Others

 

Conclusion

The market for global cancer microbiome sequencing is currently expanding due to the rising incidence of cancer, the increasing use of next-generation sequencing methods, and the growth of precision oncology research. The National Institutes of Health and other government organizations provide substantial funding, which drives innovation and supports extensive microbiome research programs. The combination of AI together with bioinformatics technologies enables scientists to conduct better data analysis while discovering new biomarkers that help develop custom-tailored cancer therapies. North America leads the market because its infrastructure systems and research development spending enable advanced research work, whereas the Asia-Pacific has developed into the fastest-growing market segment. The market will experience major technological developments and new business partnerships, which will lead to greater market entry possibilities until the year 2035.

 

Our Industry Reports: 

Global Milk Replacers Market Size, Share, Forecasts To 2033
Global Minoxidil Market Size, Share, Forecasts To 2033
Weight Checkers for Capsules and Tablets Market, Year 2033
Sub-Micrometer Computed Tomography Market Size, Year 2033

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter